{
    "nctId": "NCT01552434",
    "briefTitle": "Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease",
    "officialTitle": "A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination with Valproic Acid, or Cetuximab in Patients with Advanced Malignancy and Other Indications",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC V7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC V7, Stage IIIB Breast Cancer AJCC V7, Stage IIIC Breast Cancer AJCC V7, Stage IV Breast Cancer AJCC V6 and V7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 155,
    "primaryOutcomeMeasure": "Maximum tolerated dose (MTD) of bevacizumab, defined as the dose level below the dose at which 2 of 6 patients experience drug-related dose limiting toxicity (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or have no standard therapy that induces a complete response of at least 10% or improves survival by at least three months; in addition, patients with disease that are \"benign\" by pathology, but relentlessly progressive, leading to disability, pain, and premature death in the majority of cases (including, but not limited to lymphangioleiomyomatosis \\[LAM\\], type 2 neurofibromatosis \\[NF\\], Erdheim Chester disease, and Castleman's disease) may also be considered for enrollment\n* Patients should be at least four weeks from the last day of therapeutic radiation or cytotoxic chemotherapy or from antibody therapy, or at least five half-lives from non-cytotoxic targeted or biologic therapy; patients may have received palliative radiation immediately before (or during) treatment provided radiation is not to the only target lesion available\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2\n* Karnofsky \\>= 60%\n* Lansky performance status of \\>= 60% for participants 16 years old or younger\n* Absolute neutrophil count \\>= 1,000/mL\n* Platelets \\>= 50,000/mL\n* Creatinine =\\< 3 X upper limit of normal (ULN)\n* Total bilirubin =\\< 3.0\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 5 X ULN\n* Fasting level of total cholesterol of no more than 350 mg/dL\n* Triglyceride level of no more than 400 mg/dL\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days after the last dose\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients may not be receiving any other investigational agents and/or any other concurrent anticancer agents or therapies\n\nExclusion Criteria:\n\n* Patients with clinically significant unexplained bleeding within 28 days prior to entering the study\n* Uncontrolled systemic vascular hypertension (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg on medication)\n* Patients with clinically significant cardiovascular disease: History of CVA (cerebrovascular accident) within 6 months, myocardial infarction or unstable angina within 6 months, unstable angina pectoris\n* Pregnant or breast-feeding women\n* History of hypersensitivity to bevacizumab, murine products, or any component of the formulation\n* History of hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any component of the formulation\n* History of hypersensitivity to cetuximab, murine products, or any component of the formulation\n* Patients that are taking cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) inducers and/or inhibitors; if a patient has a history of taking CYP3A4 inducers and/or inhibitors prior to enrollment on the protocol, it is strongly recommended that the patient stops the drug and waits at least 5 half-lives of said drug before initiating therapy on protocol\n* Colorectal cancer patients with known v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation (for the arm combining bevacizumab, temsirolimus and cetuximab)\n* Patients who have had major surgery within 6 weeks of enrollment in the study",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}